Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–12 of 12 results
Advanced filters: Author: Jason R. Plemel Clear advanced filters

  • The underlying molecular mechanisms of neuroinflammation and axonal damage in progressive multiple sclerosis remains unclear. Here, authors show proteomics results of human progressive multiple sclerosis brain tissues and found extracellular matrix proteins (annexin, S100, AHNAK families) were enriched in lesions and white matter.

    • Henry Wang
    • Niall M. Pollock
    • Olivier Julien
    ResearchOpen Access
    Nature Communications
    Volume: 17, P: 1-16

  • Microglial states throughout remyelination are incompletely understood. Here, the authors show that microglia form several states during the early stages of remyelination that coalesce into a partially resolved state that is dysregulated with age.

    • Sameera Zia
    • Marianela E. Traetta
    • Jason R. Plemel
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-24

  • The impact of senescent cells on remyelination is unknown. Here, the authors show that treatment with senolytics following demyelination enhances remyelination in young, but not aged mice, and these effects are mediated by senescence-associated secretory phenotype factors including CCL11.

    • Phillip S. Gross
    • Violeta Durán-Laforet
    • Jeffrey K. Huang
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-16

  • Chemical communication between axons and their myelin sheath is an emerging concept in neurobiology. In this review, Stys and colleagues discuss how this 'axo-myelinic synapse' may play a role in metabolic control of the myelinating unit, modulate myelin dynamics and be a future therapeutic target.

    • Ileana Micu
    • Jason R. Plemel
    • Peter K. Stys
    Reviews
    Nature Reviews Neuroscience
    Volume: 19, P: 49-58

  • Chondroitin sulfate proteoglycans (CSPGs) secreted by astrocytes are known to inhibit OPC differentiation and remyelination. Here, the authors identify a novel CSPG synthesis inhibitor and find it can rescue OPC differentiation in vitroand accelerate remyelination in mice following focal demyelination.

    • Michael B. Keough
    • James A. Rogers
    • V. Wee Yong
    ResearchOpen Access
    Nature Communications
    Volume: 7, P: 1-12

  • The contribution of oligodendrocytes to remyelination in functional recovery after spinal cord injury is not fully understood. Here, the authors show that oligodendrocyte progenitor cell differentiation is not required for functional recovery after spinal cord injury in mice.

    • Greg J. Duncan
    • Sohrab B. Manesh
    • Wolfram Tetzlaff
    ResearchOpen Access
    Nature Communications
    Volume: 9, P: 1-16

  • The consequences of spinal cord injury are often severe and irreversible; cell transplantation has emerged as a potential treatment. In this Review, the authors highlight mechanisms through which cell transplantation is thought to promote functional improvements and the obstacles to making cell transplantation a viable therapy.

    • Peggy Assinck
    • Greg J Duncan
    • Wolfram Tetzlaff
    Reviews
    Nature Neuroscience
    Volume: 20, P: 637-647

  • Restoring damaged myelin could reverse the neurological effects observed in patients with multiple sclerosis. In this Review, Yong and colleagues discuss the progress made in remyelinating therapies, including novel and potential repurposed agents, and highlight the challenges in preclinical and clinical development for such drugs.

    • Jason R. Plemel
    • Wei-Qiao Liu
    • V. Wee Yong
    Reviews
    Nature Reviews Drug Discovery
    Volume: 16, P: 617-634

  • The pathophysiological complexity of progressive multiple sclerosis (MS) challenges the development of effective treatments, despite the substantial unmet clinical need. In this Review, Faissner, Yong and colleagues highlight the need for therapies that target inflammation, neurodegeneration and remyelination, which will likely be needed in combination. The setbacks encountered so far and future challenges are also discussed.

    • Simon Faissner
    • Jason R. Plemel
    • V. Wee Yong
    Reviews
    Nature Reviews Drug Discovery
    Volume: 18, P: 905-922

  • Microglia “heterogeneity” is often described in the literature, but a clear understanding of what “heterogeneity” entails is essential to avoid confusion among researchers.

    • Luke M. Healy
    • Sameera Zia
    • Jason R. Plemel
    ReviewsOpen Access
    Communications Biology
    Volume: 5, P: 1-6